Posted by Michael Wonder on 18 Jun 2024
PHARMAC improves access to breast cancer treatments
18 June 2024 - PHARMAC has changed the criteria for two breast cancer medicines which means people with a particular type of breast cancer will be able to stay on treatment for longer.
From 1 July 2024, ribociclib (Kisqali) will be funded for patients with locally advanced or metastatic hormone receptor positive HER2 negative breast cancer. Palbociclib (Ibrance) has been funded for this type of breast cancer since 2020.
